Papillary Thyroid Cancer Clinical Trial
Official title:
A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma
This randomized phase II trial studies how well dabrafenib works with or without trametinib in treating patients with recurrent thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether dabrafenib is more effective when given with or without trametinib in treating thyroid cancer
PRIMARY OBJECTIVES: I. To screen two different regimens (GSK2118436 [BRAFi] [dabrafenib] as a single agent versus the combination regimen of GSK2118436 [BRAFi] and GSK1120212 [MEKi] [trametinib]) and identify which regimen is more promising for subsequent testing in a phase III trial in radioiodine refractory BRAF-mutated differentiated thyroid cancer (DTC) patients. SECONDARY OBJECTIVES: I. To understand duration of objective response, progression-free survival and overall survival for each treatment group. II. To assess tolerability and adverse events of GSK2118436 (BRAFi) as a single agent and the tolerability and adverse events of GSK2118436 (BRAFi) and GSK1120212 (MEKi) in combination, in patients with DTC. III. To evaluate impact of experimental drugs on serum tumor marker thyroglobulin and its correlation with overall response rate. IV. To understand pharmacokinetic, pharmacogenetics and pharmacodynamics of experimental drugs using serial tumor biopsies, tumor blocks and peripheral blood. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive dabrafenib orally (PO) twice daily (BID) on days 1-28. Patients with disease progression may cross-over to arm II. ARM II: Patients receive dabrafenib PO BID and trametinib PO once daily (QD) on days 1-28. In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 4 weeks. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01441154 -
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
|
||
| Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT03469011 -
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
|
Phase 1 | |
| Recruiting |
NCT05752669 -
Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
|
||
| Recruiting |
NCT04076514 -
The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
|
||
| Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
| Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
| Unknown status |
NCT02140476 -
Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy
|
N/A | |
| Recruiting |
NCT06286631 -
Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
|
||
| Completed |
NCT06325787 -
Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma
|
N/A | |
| Terminated |
NCT01974284 -
Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
|
N/A | |
| Active, not recruiting |
NCT00984191 -
Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid
|
N/A | |
| Active, not recruiting |
NCT04731467 -
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
| Completed |
NCT02178345 -
Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
|
||
| Not yet recruiting |
NCT06133374 -
Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
|
||
| Completed |
NCT03470259 -
Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging
|
Phase 1 | |
| Active, not recruiting |
NCT04129411 -
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
|
N/A | |
| Recruiting |
NCT03899792 -
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
|
Phase 1/Phase 2 |